Horizon Pharma PLC (HZNP)

NASDAQ
69.20
+0.79(+1.15%)
  • Volume:
    144,774
  • Day's Range:
    67.86 - 69.26
  • 52 wk Range:
    60.76 - 120.54

HZNP Overview

Prev. Close
68.41
Day's Range
67.86-69.26
Revenue
3.81B
Open
68.15
52 wk Range
60.76-120.54
EPS
3.35
Volume
144,774
Market Cap
15.72B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
2,356,909
P/E Ratio
21.54
Beta
1.11
1-Year Change
-34.85%
Shares Outstanding
230,384,373
Next Earnings Date
Nov 07, 2022
What is your sentiment on Horizon Pharma?
or
Vote to see community's results!

Horizon Pharma PLC Analysis

Horizon Pharma PLC Company Profile

Horizon Pharma PLC Company Profile

Employees
1940

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyNeutralSellNeutral
Technical IndicatorsStrong BuyStrong BuyBuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyNeutralStrong SellSell
  • Give the anti-corona spray from marinomed-biotech some VC and invest in a pharma company which is heading to the moon:https://www.investing.com/equities/marinomed-biotech-agStudies are proving that the patented method of marinomed prevents infection with all Corona varietis including mutants. It also prevents other virus infections. They have many patents.  Do some good and get rich
    0
    • Really weak recovery from red days - VERY LOW volume, hard to move up with only 1.16 million shares being traded, half of which could be sells - AND FOR THAT reason, I AM OUT!
      1
      • LOL
        0
    • Sundial growers next week 1,5 $
      1
      • 28.21
        0
        • 27.5
          0
          • TP 17.80$
            0
            • short-termly to minor mid-termly 19$.
              0
            • you shall see on the ''horizon''
              0
            • Correct
              0